MX358636B - Formulaciones farmacéuticas de naproxeno para la encapsulación en gel blando y combinaciones de las mismas. - Google Patents
Formulaciones farmacéuticas de naproxeno para la encapsulación en gel blando y combinaciones de las mismas.Info
- Publication number
- MX358636B MX358636B MX2012008300A MX2012008300A MX358636B MX 358636 B MX358636 B MX 358636B MX 2012008300 A MX2012008300 A MX 2012008300A MX 2012008300 A MX2012008300 A MX 2012008300A MX 358636 B MX358636 B MX 358636B
- Authority
- MX
- Mexico
- Prior art keywords
- nsaid
- naproxen
- concentration
- soft gel
- formulation
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4833—Encapsulating processes; Filling of capsules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Una formulación de NSAID para la encapsulación en una cápsula de gel blando con estabilidad, concentración y biodisponibilidad incrementadas del NSAID. Los NSAIDS preferidos son naproxeno, ibuprofeno, indometacina y diclofenaco, que se proporcionan en una forma tanto acídica como básica en la formulación de relleno. Los valores de pH de las formulaciones de relleno se pueden ajustar sin etapas de proceso adicionales. También se proporciona un proceso para incrementar la concentración lograble de un ingrediente farmacéutico de NSAID activo en una composición de relleno para unidades de dosificación. La formulación de NSAID altamente concentrada permite una reducción en el volumen de relleno o tamaño de unidad de dosificación, o un incremento en la concentración del NSAID en cada unidad de dosificación.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CA2690488A CA2690488C (en) | 2010-01-19 | 2010-01-19 | Pharmaceutical formulations of naproxen for soft gel encapsulation and combinations thereof |
| PCT/CA2011/000059 WO2011088553A1 (en) | 2010-01-19 | 2011-01-19 | Pharmaceutical formulations of naproxen for soft gel encapsulation and combinations thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2012008300A MX2012008300A (es) | 2012-11-23 |
| MX358636B true MX358636B (es) | 2018-08-29 |
Family
ID=44303618
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2012008300A MX358636B (es) | 2010-01-19 | 2011-01-19 | Formulaciones farmacéuticas de naproxeno para la encapsulación en gel blando y combinaciones de las mismas. |
Country Status (13)
| Country | Link |
|---|---|
| US (4) | US9480667B2 (es) |
| EP (2) | EP2525789B1 (es) |
| JP (2) | JP5975884B2 (es) |
| AU (1) | AU2011207061B2 (es) |
| CA (1) | CA2690488C (es) |
| DK (1) | DK2525789T3 (es) |
| ES (1) | ES2880813T3 (es) |
| HU (1) | HUE055771T2 (es) |
| MX (1) | MX358636B (es) |
| PL (1) | PL2525789T3 (es) |
| PT (1) | PT2525789T (es) |
| SI (1) | SI2525789T1 (es) |
| WO (1) | WO2011088553A1 (es) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201301626D0 (en) | 2013-01-30 | 2013-03-13 | Dignity Sciences Ltd | Composition comprising 15-OHEPA and methods of using the same |
| RU2714323C2 (ru) * | 2014-06-04 | 2020-02-14 | ДиЭс БАЙОФАРМА ЛИМИТЕД | Фармацевтические композиции, содержащие дглк, и их применение |
| CN104083339A (zh) * | 2014-08-04 | 2014-10-08 | 人福普克药业（武汉）有限公司 | 萘普生钠软胶囊及其制备方法 |
| US10368284B2 (en) * | 2014-11-12 | 2019-07-30 | T-Mobile Usa, Inc. | Quality of experience-based handover management |
| CN113896628A (zh) | 2015-05-13 | 2022-01-07 | Ds生物制药有限公司 | 包含15-氧代-epa或15-氧代-dgla的组合物及其制备和使用方法 |
| EP3861995A1 (en) | 2015-07-21 | 2021-08-11 | Affimune Limited | Compositions comprising 15-hepe for use in treating or preventing neurologic disease |
| KR20180094516A (ko) | 2015-12-18 | 2018-08-23 | 애피뮨 리미티드 | 15-hepe를 포함하는 조성물 및 이를 사용하는 방법 |
| US11911517B2 (en) | 2018-05-16 | 2024-02-27 | Bayer Healthcare Llc | High concentration suspension formulation for cold and flu soft gel capsule medications |
| CN109692127A (zh) * | 2019-03-15 | 2019-04-30 | 王征 | 一种密封小胶囊的制备方法 |
| BR112021021414A2 (pt) * | 2019-04-26 | 2022-02-15 | Scherer Technologies Llc R P | Composição do mini softgel de naproxeno |
| US20210315851A1 (en) | 2020-04-03 | 2021-10-14 | Afimmune Limited | Compositions comprising 15-hepe and methods of treating or preventing hematologic disorders, and/or related diseases |
| US20220233452A1 (en) * | 2021-01-25 | 2022-07-28 | R.P. Scherer Technologies, Llc | Mini softgel naproxen composition |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4443428A (en) * | 1982-06-21 | 1984-04-17 | Euroceltique, S.A. | Extended action controlled release compositions |
| US5071643A (en) * | 1986-10-17 | 1991-12-10 | R. P. Scherer Corporation | Solvent system enhancing the solubility of pharmaceuticals for encapsulation |
| BR9407414A (pt) * | 1993-09-07 | 1996-11-12 | Procter & Gamble | Composições contendo um sal de aminoácido de agente antiinflamatório não-esteroide de ácido propiônico e pelo menos um descongestionante um expectorante um anti-histamina e um antitussivo |
| US5484606A (en) * | 1994-01-24 | 1996-01-16 | The Procter & Gamble Company | Process for reducing the precipitation of difficulty soluble pharmaceutical actives |
| JPH09508128A (ja) * | 1994-01-24 | 1997-08-19 | ザ、プロクター、エンド、ギャンブル、カンパニー | 難溶性医薬活性剤の溶解方法 |
| US5641512A (en) * | 1995-03-29 | 1997-06-24 | The Procter & Gamble Company | Soft gelatin capsule compositions |
| EP1049459B1 (en) * | 1998-01-20 | 2009-04-22 | Applied Analytical Industries, Inc. | Oral liquid compositions |
| US6383515B2 (en) * | 1999-05-28 | 2002-05-07 | Sawyer Maryjean | Solvent system for enhancing solubility |
| US6387400B1 (en) | 2000-08-29 | 2002-05-14 | R.P. Scherer Technologies, Inc. | Process for preparing pharmaceutical compositions for use with soft gelatin formulations |
| JP2006514119A (ja) * | 2003-02-12 | 2006-04-27 | アール アンド ピー コリア カンパニー リミテッド | 溶解率が向上した難溶性薬剤の溶媒系 |
| US20090318558A1 (en) * | 2003-02-12 | 2009-12-24 | Jae-Hwan Kim | Solvent system of hardly soluble drug with improved dissolution rate |
| US20070053868A1 (en) | 2005-03-08 | 2007-03-08 | Banner Pharmacaps, Inc. | Solvent system for enhancing the solubility of pharmaceutical agents |
| US7582679B2 (en) * | 2006-02-03 | 2009-09-01 | Pharmaceutics International Incorporated | Compositions containing solid ibuprofen concentrates and methods of making solid ibuprofen concentrates |
| US20080014274A1 (en) * | 2006-07-14 | 2008-01-17 | Wyeth | Enhanced stability phenylephrine liquid compositions |
| US20110052679A1 (en) * | 2009-08-25 | 2011-03-03 | Pharmaceutics International, Inc. | Solid naproxen concentrates and related dosage forms |
-
2010
- 2010-01-19 CA CA2690488A patent/CA2690488C/en active Active
-
2011
- 2011-01-19 DK DK11734283.2T patent/DK2525789T3/da active
- 2011-01-19 AU AU2011207061A patent/AU2011207061B2/en active Active
- 2011-01-19 PL PL11734283T patent/PL2525789T3/pl unknown
- 2011-01-19 WO PCT/CA2011/000059 patent/WO2011088553A1/en not_active Ceased
- 2011-01-19 SI SI201131992T patent/SI2525789T1/sl unknown
- 2011-01-19 EP EP11734283.2A patent/EP2525789B1/en active Active
- 2011-01-19 HU HUE11734283A patent/HUE055771T2/hu unknown
- 2011-01-19 MX MX2012008300A patent/MX358636B/es active IP Right Grant
- 2011-01-19 ES ES11734283T patent/ES2880813T3/es active Active
- 2011-01-19 US US13/574,159 patent/US9480667B2/en active Active
- 2011-01-19 EP EP21177143.1A patent/EP3909567A1/en active Pending
- 2011-01-19 PT PT117342832T patent/PT2525789T/pt unknown
- 2011-01-19 JP JP2012549215A patent/JP5975884B2/ja active Active
-
2016
- 2016-01-18 JP JP2016007253A patent/JP2016094462A/ja active Pending
- 2016-10-05 US US15/285,968 patent/US10463637B2/en active Active
-
2019
- 2019-09-26 US US16/583,903 patent/US11896566B2/en active Active
-
2023
- 2023-12-29 US US18/400,069 patent/US20240139132A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US20200046662A1 (en) | 2020-02-13 |
| HUE055771T2 (hu) | 2021-12-28 |
| WO2011088553A1 (en) | 2011-07-28 |
| AU2011207061B2 (en) | 2015-05-28 |
| US20130011470A1 (en) | 2013-01-10 |
| EP3909567A1 (en) | 2021-11-17 |
| ES2880813T3 (es) | 2021-11-25 |
| JP2013517304A (ja) | 2013-05-16 |
| PL2525789T3 (pl) | 2022-01-03 |
| AU2011207061A1 (en) | 2012-07-26 |
| SI2525789T1 (sl) | 2021-12-31 |
| JP5975884B2 (ja) | 2016-08-23 |
| EP2525789B1 (en) | 2021-06-02 |
| MX2012008300A (es) | 2012-11-23 |
| PT2525789T (pt) | 2021-07-19 |
| CA2690488A1 (en) | 2011-07-19 |
| EP2525789A1 (en) | 2012-11-28 |
| US20170020832A1 (en) | 2017-01-26 |
| EP2525789A4 (en) | 2014-04-30 |
| JP2016094462A (ja) | 2016-05-26 |
| DK2525789T3 (da) | 2021-07-19 |
| US10463637B2 (en) | 2019-11-05 |
| US9480667B2 (en) | 2016-11-01 |
| US11896566B2 (en) | 2024-02-13 |
| US20240139132A1 (en) | 2024-05-02 |
| CA2690488C (en) | 2013-06-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX358636B (es) | Formulaciones farmacéuticas de naproxeno para la encapsulación en gel blando y combinaciones de las mismas. | |
| CY1123023T1 (el) | Υδατικη φαρμακευτικη μορφοποιηση ταπενταδολης για χορηγηση απο το στομα | |
| CR10728A (es) | Formas de dosificacion del clorhidrato de palonosetron que tienen estabilidad y biodisponibilidad mejorada | |
| CL2013000218A1 (es) | Forma de dosificacion farmaceutica para administracion oral de una vez al dia, que contiene 6’-fluoro-(n-metil- o n,n-dimetil)-4-fenil-4’,9’-dihidro-3’h-espiro[ciclohexan-1,1’-pirano[3,4,b]indol]-4-amina, para uso en el tratamiento del dolor nocioceptivo. | |
| ECSP10010224A (es) | Formulaciones líquidas de hormona luteinizante (lh). | |
| MX2019007956A (es) | Liberacion autorregulada de ingrediente farmaceutico activo. | |
| MX2015009772A (es) | Moduladores de receptores nmda de espiro-lactama y sus usos. | |
| CY1123895T1 (el) | Φαρμακευτικα σκευασματα λοραταδινης για εγκλεισμο σε καψακια και συνδυασμοι αυτων | |
| UY31086A1 (es) | Dispositivo dispensador | |
| CO6771406A2 (es) | Una composición combinada | |
| CL2014001828A1 (es) | Sistema de dosificacion oral de liberacion dual que comprende doxilamina y piridoxina y/o sus analogos, metabolitos y sales de los mismos; forma de dosificacion oral de liberacion dual; kit farmaceutico; uso para aliviar los sintomas de nauseas y vomitos, incluidos los del embarazo. | |
| EA201400737A1 (ru) | Система доставки на основе множества пеллет с немедленным высвобождением активного вещества | |
| EA201501164A1 (ru) | Твердая фармацевтическая лекарственная форма | |
| EA201390950A1 (ru) | Гомогенные фармацевтические пероральные лекарственные формы, содержащие лерканидипин и эналаприл или их фармацетически приемлемые соли совместно с органической кислотой | |
| EA201691034A1 (ru) | Композиции в твердой форме с замедленным высвобождением для перорального введения | |
| MX2016014256A (es) | Formulaciones y metodos para el suministro vaginal de antiprogestinas. | |
| CL2016000397A1 (es) | Tratamiento contra el cáncer | |
| AR094224A1 (es) | Composicion farmaceutica en forma de una suspension oral | |
| AR085431A1 (es) | Complejo de resinato de doxilamina | |
| CR20160021A (es) | Combinación sinergística de paracetamol/celecoxib para el tratamiento de dolor inflamatorio | |
| EA201491995A1 (ru) | Пероральная лекарственная форма | |
| EA201590732A1 (ru) | Диспергируемая таблетка | |
| PE20151432A1 (es) | Formulaciones de lorazepam de liberacion sostenida | |
| CL2012003685A1 (es) | Kit farmaceutico que comprende una o mas unidades de envasado que comprenden 21 a 28 unidades de dosificacion activas diarias en que cada una comprende por lo menos 2 mg de drosperidona, sin estrogernos; uso del kit y de una composicion farmaceutica que comprende drosperidona para preparar un medicamento util como anticonceptivo. | |
| ES2468665B1 (es) | Composición farmacéutica de sulfato de condroitina y celecoxib |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration |